David H Aggen, MD PhD· @Dr_Aggen · X·· 2 天前评分90
正文 · 原文
KEYNOTE-866: No significant EFS benefit with perioperative pembro + gem/cis (HR 0.88, p=0.14) and no OS signal (HR 1.00).
Why did the control arm perform so well? More cT2 disease? No split-dose cisplatin? Important differences vs NIAGARA.
#ESMO26 @OncoAlert
438 浏览 · 9 赞 · 8 转发 · 0 回复
会议摘要
4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org来源：David H Aggen, MD PhD · x.com